DEFA14A: Benitec Biopharma Announces Executive Bonuses for Fiscal Year 2024
Current Report
Benitec Biopharma's Compensation Committee approved discretionary bonus payments for its Executive Chairman/CEO and Executive Director for their performance during the fiscal year ending June 30, 2024.
Summary
- Benitec Biopharma's Compensation Committee approved bonus payments for two key executives.
- Dr. Jerel Banks, the Executive Chairman and CEO, received a bonus of $360,360.
- Megan Boston, the Executive Director, received a bonus of $161,580.
- Ms. Boston's bonus was converted from Australian dollars to US dollars using an exchange rate of AUD $1.00 to USD $0.67 as of November 7, 2024.
- The bonuses were awarded for performance during the fiscal year ending June 30, 2024.
Sentiment
Score: 6
Explanation: The document is neutral in tone, reporting on standard executive compensation practices. It is neither overly positive nor negative.
Positives
- The approval of bonuses suggests the company recognizes and rewards the performance of its key executives.
- The bonuses indicate that the company met some performance goals during the fiscal year ending June 30, 2024.
Industry Context
Executive compensation is a common practice in the biopharmaceutical industry to incentivize and retain key talent. The size of the bonuses is not disclosed in relation to industry standards.
Comparison to Industry Standards
- It is difficult to assess the size of the bonuses without knowing the company's overall financial performance and the industry benchmarks for similar roles.
- Without more information, it is not possible to compare these bonuses to those of executives at comparable companies such as Alnylam Pharmaceuticals, Sarepta Therapeutics, or BioMarin Pharmaceutical.
Stakeholder Impact
- Shareholders may view the bonuses as a positive sign of management performance, but may also scrutinize the amounts in relation to overall company performance.
- Employees may see the bonuses as a positive sign of the company's financial health and commitment to rewarding performance.
Key Dates
| Date | Description |
|---|---|
| November 7, 2024 | Date of the earliest event reported, which is the approval of the executive bonuses and the date used for the AUD to USD conversion rate. |
| November 14, 2024 | Date the report was signed. |
Keywords
executive compensation, bonus, biopharma, Benitec Biopharma, Jerel Banks, Megan Boston, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.